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Abstract
Background: Beckwith-Wiedemann syndrome (BWS) is an imprinting disorder with a population frequency of
approximately 1 in 10,000. The most common epigenetic defect in BWS is a loss of methylation (LOM) at the
11p15.5 imprinting centre, KCNQ1OT1 TSS-DMR, and affects 50% of cases. We hypothesised that genetic factors linked to
folate metabolism may play a role in BWS predisposition via effects on methylation maintenance at KCNQ1OT1 TSS-DMR.
Results: Single nucleotide variants (SNVs) in the folate pathway affecting methylenetetrahydrofolate reductase (MTHFR),
methionine synthase reductase (MTRR), 5-methyltetrahydrofolate-homocysteine S-methyltransferase (MTR), cystathionine
beta-synthase (CBS) and methionine adenosyltransferase (MAT1A) were examined in 55 BWS patients with KCNQ1OT1
TSS-DMR LOM and in 100 unaffected cases. MTHFR rs1801133: C>T was more prevalent in BWS with KCNQ1OT1 TSS-DMR
LOM (p < 0.017); however, the relationship was not significant when the Bonferroni correction for multiple testing was
applied (significance, p = 0.0036). None of the remaining 13 SNVs were significantly different in the two populations
tested. The DNMT1 locus was screened in 53 BWS cases, and three rare missense variants were identified in each of
three patients: rs138841970: C>T, rs150331990: A>G and rs757460628: G>A encoding NP_001124295 p.Arg136Cys, p.
His1118Arg and p.Arg1223His, respectively. These variants have population frequencies of less than 1 in 1000 and were
absent from 100 control cases. Functional characterization using a hemimethylated DNA trapping assay revealed
a reduced methyltransferase activity relative to wild-type DNMT1 for each variant ranging from 40 to 70%
reduction in activity.
Conclusions: This study is the first to examine folate pathway genetics in BWS and to identify rare DNMT1
missense variants in affected individuals. Our data suggests that reduced DNMT1 activity could affect maintenance of
methylation at KCNQ1OT1 TSS-DMR in some cases of BWS, possibly via a maternal effect in the early embryo. Larger
cohort studies are warranted to further interrogate the relationship between impaired MTHFR enzymatic activity
attributable to MTHFR rs1801133: C>T, dietary folate intake and BWS.
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Background
The human imprinting disorder Beckwith-Wiedemann syn-
drome (BWS) (OMIM 130650) is characterised by over-
growth in the prenatal and postnatal period, macroglossia,
umbilical hernia or exomphalos, neonatal hypoglycaemia,
ear lobe creases and pits, nevi flammei, hemihyperplasia
and organomegaly, particularly of the kidney, liver and pan-
creas. One of its more serious complications is an increased
predisposition to cancer in early childhood with tumour
risk segregating with distinct genetic and epigenetic sub-
types (reviewed in [1–4]).
The majority of the affected children have an isolated
epigenetic abnormality at the 11p15.5 imprinting centre 2
(IC2), known as KCNQ1OT1 TSS-DMR, the location of
the KCNQ1OT1/CDKN1C locus. Fifty percent of all chil-
dren with features of BWS have either mosaic or complete
loss of methylation (LOM) within the KCNQ1OT1 pro-
moter and impaired expression of maternal CDKN1C, a
critical regulator of growth during early development [5,
6]. For the majority of BWS cases with KCNQ1OT1
TSS-DMR imprinting disruption, the aetiology is un-
known and the phenotype arises without any evidence of
heritability. Rare cases have been reported with imprinting
defects in KCNQ1OT1 TSS-DMR associated with inher-
ited recessive mutations affecting NLRP2 on 19q13.42 [7],
and more recently, maternal effect missense and truncat-
ing variants in other NLRP loci, including NLRP5 and
NLRP7, were reported in the mothers of offspring with
multi-locus imprinting disruption (MLID) that included
loss of methylation at KCNQ1OT1 TSS-DMR [8, 9].
MLID cases with methylation loss at KCNQ1OT1
TSS-DMR frequently had characteristics of BWS. Animal
studies have shown that defective methylation is set in the
gametes or during the first cell divisions of the embryo,
and genetic modifiers and environmental factors influence
this process [10]. Indeed, in BWS, the increased inci-
dence of BWS cases with KCNQ1OT1 TSS-DMR
LOM after assisted reproduction (ART) points to the
involvement of environmental factors that perturb
methylation at KCNQ1OT1 TSS-DMR or alternatively
suggest a link between therapeutic interventions for
female infertility and defective methylation [11–15].
The one-carbon pathway is the major metabolic pathway
through which dietary folate is converted to methyl donor
groups that subsequently methylate DNA via catalysis of
the universal methyl donor S-adenosyl-methionine in the
presence of DNA methyltransferase 1 (DNMT1). The key
enzymes of this pathway include methylenetetrahydrofo-
late reductase (MTHFR), methionine synthase reductase
(MTRR), 5-methyltetrahydrofolate-homocysteine S-meth-
yltransferase (MTR), cystathionine beta-synthase (CBS)
and methionine adenosyltransferase (MAT1A), and the as-
sociated effects of genetic variants with impaired enzyme
activity have been documented in several studies. A
common SNV (previously commonly known as
c.677C>T) in MTHFR, rs1801133: C>T, NP_005948.3:
p.Ala222Val, increases protein thermolability [16] and has
been linked to vascular thromobosis, hyperhomocystei-
naemia and global hypomethylation in a setting of dietary
folate depletion ([17–20]. A second MTHFR SNV,
rs1801131: A>C, NP_005948.3: p.Gln429Ala, is linked to
DNA hypomethylation, independently of folate availability
and acts synergistically with rs1801133 to reduce MTHFR
activity [21, 22]. MTR catalyses the remethylation of
homocysteine to methionine and SNV rs1805087: A>G,
NP_000245.2: p.Asp919Gly alters the helix structure in
the substrate binding domain leading to impaired methio-
nine biosynthesis and reduced methyl donor availability
[23–25]. MTRR rs1801394: A>G, NP_002445.2 p.Ile22-
Met, acts synergistically with homozygous MTHFR
rs1801133: C>T, NP_005948.3: p.Ala222Val, in the pres-
ence of low folate and/or vitamin B12 status [26].
The isoforms of Dnmt1 (Dnmt1o and Dnmt1s) play a
critical role in the maintenance of DNA methylation at
imprinted regions during pre-implantation mammalian
development [27]. The absence of 118 N terminal amino
acids allows Dnmt1o protein to accumulate to high levels
in non-dividing growing oocytes [28], and expression is
maintained in pre-implantation embryos in the morula
and blastocyst. Howell et al. 2001 showed that Dnmt1o,
while not essential for imprint establishment in oocytes,
was required for the maintenance of methylation at
imprinted loci, and heterozygous offspring of Dnmt1o-null
mothers exhibited imprinting defects. The functions of
Dnmt1o and Dnmt1 are interchangeable as Dnmt1 is itself
able to maintain methylation during pre-implantation de-
velopment [29, 30], and Dnmt1o can rescue Dnmt1−/− ES
cells [31]. However, although these studies implicate
DNMT1 in imprinting disorders, it has not previously been
examined in the context of BWS or MLID.
In this study, we investigated the genetics of folate
metabolism and maintenance of DNA methylation in
cases of BWS with loss of methylation at KCNQ1OT1
TSS-DMR. This included an analysis of SNVs in
MTHFR, MTRR, MTR, MAT1A and CBS predicted to
alter the function and a full mutation screen of
DNMT1. While a statistically significant association
between deleterious SNVs in folate pathway genes
could not be conclusively demonstrated, we identified
three patients with rare missense amino acid substitu-
tions in DNMT1 that are represented in dbSNP at a
frequency of < 0.001. Functional characterization of
these variants showed a significant reduction in com-
plex formation with hemimethylated DNA, consistent
with impaired DNMT1 activity. This is the first study
examining the folate pathway and the major human
methyltransferase, DNMT1, in the most common epi-
genetic subtype of BWS.
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Results
Analysis of MTHFR, MTRR, MTR, MAT1A and CBS in BWS
cases with KCNQ1OT1 TSS-DMR LOM
The one-carbon pathway of folate metabolism is shown in
Fig. 1. Coding SNVs in MTHFR, MTRR and MTR generat-
ing missense amino acid substitutions and for which previ-
ous evidence of impaired or altered enzyme function had
been demonstrated in other studies were selected for inves-
tigation in the BWS study population (55 cases) and in a
matched local control population (100 cases). The enzymes
MAT1A and CBS were also included because rare coding
SNVs were identified in genome databases with damaging
polyphen scores and predicted structural effects.
All gene SNVs interrogated in the study are shown
in Table 1.
Fifty-five unrelated cases with clinical features of BWS
were assessed as having either complete or partial LOM at
KCNQ1OT1 TSS-DMR. Ten of these 55 cases had
multi-locus imprinting disruption (MLID) involving losses
of methylation at additional imprinting domains in-
cluding MEST, PLAGL1, GRB10, NESPAS and PEG3
(Additional file 1: Table S1). A total of 11 cases had
been conceived using assisted reproductive technolo-
gies (ART). Specimens were screened using HRM
across selected one-carbon pathway SNVs, and those
with shifted melt profiles were sequenced. Specific re-
action conditions are shown in Additional file 1: Ta-
bles S2 and S3. The significance of minor allele SNV
frequencies in the BWS study population for each
gene was calculated using the chi-squared analysis
relative to the frequencies determined in 100 control
DNA specimens from the cord blood.
The MTHFR rs1801133 minor allele is more prevalent
in BWS with KCNQ1OT1 TSS-DMR LOM.
Table 2 shows SNV frequencies in BWS patients with
KCNQ1OT1 TSS-DMR LOM, including those with MLID,
compared to controls and frequencies in dbSNP147. One
SNV of 14 screened, MTHFR rs1801133: C>T, was signifi-
cantly different when compared to the local control popula-
tion with a p value of 0.0167 derived using a 2 × 2
contingency table. There were 43 T alleles in a total of 110
in the BWS subgroup compared to 52 T alleles in a total of
200 alleles in the control group.MAT1A and CBSminor al-
lele frequencies were too low in both populations for mean-
ingful statistical analysis to be done. After correcting for
multiple testing of each of the 14 one-carbon pathway
SNVs examined, the Bonferroni significance value was
0.0036 (0.05/14). The p value for MTHFR rs1801133: C>T
at 0.0167 was no longer significant when this more strin-
gent statistical test was applied to the data. Hence, although
MTHFR rs1801133: C>T appears to be more prevalent in
the BWS population, this finding is not statistically signifi-
cant when adjustment for multiple testing is applied.
Rare variants of DNMT1 are present in some BWS cases
with KCNQ1OT1 TSS-DMR LOM
Dnmt1 and Dnmt1o proteins play a central role in the
maintenance of DNA methylation during pre-implantation
embryonic development, and DNMT1 is the major enzyme
in the folate pathway responsible for the catalysis of S-ade-
nosyl methionine, providing methyl groups for methylation
of DNA. Hayward et al. [32] defined the location of human
DNMT1o from sequence derived from EST BE537788.
Primers were designed to this region (hg19 GRCh37 chr19:
10311482-10311816) and to the entire coding region of
DNMT1 (NM_001130823.1, representing the longest tran-
script). Variants affecting the coding regions of DNMT1o
and DNMT1 were screened by HRM and sequenced to
Fig. 1 The one-carbon pathway responsible for the conversion of dietary folate to methyl donor groups. The critical enzymes in the pathway
examined in this study are shown in bold. MTHFR is primarily responsible for the conversion of tetrahydrofolate to methylene-tetrahydrofolate.
MTRR and MTR work together to catalyse the conversion of homocysteine to methionine in the presence of the cofactor vitamin B12 and zinc,
enabling the movement of the methyl group from methylene-tetrahydrofolate and recycling of tetrahydrofolate. CBS converts homocysteine in
the presence of vitamin B6 to cystathione and MAT1A is responsible for converting methionine to S-adenosy-methionine (SAM), the ultimate
methyl donor for DNA via catalysis by DNA methyltransferase
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Table 1 SNVs interrogated in BWS patients with loss of methylation at KCNQ1OT1 TSS-DMR
Gene SNV_1 ID SNV_2 ID SNV_3 ID SNV_4 ID
MTHFR 677C>T Rs 1801133: C>T Rs 1801131: A>C Rs 2274976: G>A
NM_005957.4: c.665C>T NM_005957.4: c.1286A>C NM_005957.4:c.1781G>A
NP_005948.3 p.Ala222Val NP_005948.3 p.Gln429Ala NP_005948.3 p.Arg594Gln
A = 0.24 G = 0.24 T = 0.075
MTRR Rs 1801394: A>G Rs 2287780: C>T Rs 10380: C>T
NM_002454.2: c.66A>G NM_002454.2: c.1243C>T NM_024010.2: c.1864C>T
NP_002445.2 p.Ile22Met NP_002445.2 p.Arg415Cys NP_076915.2 p.His622Tyr
G = 0.36 GMAF, 0.47 ClinVar, 0.45 EXAC T = 0.0679 T = 0.219
MAT1A Rs 114494303: G>A Rs 72558181: G>A Rs 112848063: A>G Rs 116659053: G>A
NM_00429.2: c.530G>A NM_00429.2: c.791G>A NM_00429.2: c.1061A>G NM_00429.2: c.1066G>A
NP_00420.1 p.Arg177Gln NP_00420.1 p.Arg264His NP_00420.1 p.Asp354Gly NP_00420.1 p.Arg356Trp
A = 0.0002 A = 0.000009 A = 0.0002
MTR Rs 1805087: A>G
NM_000254.2: c.2756A>G,
NP_000245.2 p.Asp919Gly
G = 0.218
CBS Rs 17849313: G>C Rs 117687681: C>T Rs 11700812: G>A/C
NM_001178009.1: c.205G>C NM_001178009.1: c.1105C>T NM_000071.2: c.1106G>A, G>C
NP_000062.1 p.Ala69Pro NP_000062.1 p.Arg369Cys NP_001171479.1 p.Arg369His,
A = 0.0012 NP_001171479.1 p.Arg369Pro.
T/G = 0.00003
Allele frequency data was obtained from dbSNP147 or other sources as indicated. Minor allele nucleotides on the forward genomic strand are shown. Where the
alternate allele frequency is not shown, the SNV frequency is unknown. The MTHFR variant commonly referred to as c.677C>T is MTHFR: NM_005957.4 c.665C>T
in HGVS format. Nucleotide numbering uses + 1 as the A of the ATG translation initiation codon
Table 2 Table showing one carbon pathway enzyme allele frequencies in 55 BWS and 100 control specimens and their significance
values
Gene SNV BWS MAF 110 alleles Local control MAF 200 alleles p value BWS versus local controls Global control MAF
MTHFR Rs1801133: C>T 0.391 0.260 0.0167 0.24
Rs1801131: A>C 0.309 0.400 0.0516 0.2494
Rs2274976: G>A 0.045 0.060 0.6606 0.075
MTRR Rs1801394: A>G 0.560 0.490 0.214 0.46*
Rs2287780: C>T 0.0833 0.035 0.068 0.076
Rs10380: C>T 0.1204 0.090 0.397 0.174
MAT1A Rs114494303: G>A 0.01 0.00 NS 0.0002
Rs72558181: G>A 0.01 0.00 NS 0.000009
Rs112848063: A>G 0.00 0.00 NS NA
Rs116659053: G>A 0.00 0.00 NS 0.0002
MTR Rs1805087: A>G 0.2091 0.220 0.981 0.218
CBS Rs17849313: G>C 0.000 0.00 NS NA
Rs117687681: C>T 0.010 0.00 NS NA
Rs11700812: G>A/C 0.000 0.00 NS NA
Global allele frequencies were derived from dbSNP147. p values were derived from chi-squared analysis with one degree of freedom
p values of significance (< 0.05) are in italics
MAF minor allele frequency, NS not significant, NA data not available
*The minor allele frequency was calculated from the mean MAF in EXAc (0.452) and Clinvar (0.47)
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confirm their identity. A schematic of DNMT1 and
DNMT1o protein structure is shown in Fig. 2.
Fifty-three of the 55 BWS cases with KCNQ1OT1
TSS-DMR LOM were tested for SNVs in the coding regions
of DNMT1. A total of 17 DNMT1 SNVs were identified. No
SNVs were identified in the sequence exon 1o, unique to
DNMT1 and upstream of the DNMT1o ATG. All of the
DNMT1 SNVs identified have been reported in dbSNP147.
This database represents compiled variant data from 37 dif-
ferent genomic databases. Five substitutions were synonym-
ous coding SNVs, six were located within the intronic
sequence flanking exons and not predicted to affect spli-
cing and one rare variant rs772176328: C>T, flanking exon
34 (NC_000019.10:g.10139820G>A (NM_001318731.1:
c.3444-3C>T) had the potential to affect splicing but was
not located within a canonical splice acceptor site. Five
substitutions were missense variants with codon changes,
four of which affected single patients only. Filtering of the
missense DNMT1 variants identified three with allele fre-
quencies of less than 1 in 1000 making them potentially
interesting candidates for a disorder with a population fre-
quency of approximately 1 in 10,000 [33]. These were
DNMT1 SNVs rs138841970: C>T, rs150331990: A>G and
rs757460628: G>A encoding NP_001124295 p.Arg136Cys,
p.His1118Arg and p.Arg1223His, respectively. Sequence
traces are shown in Additional file 2: Figure S1. All
missense variants identified and their allele frequencies
are described in Table 3. All were heterozygous.
All five missense variants identified, including the three
rare missense variants, are predicted to have a moderate ef-
fect on protein function according to integrated analysis in
Variant Effect Predictor (http://asia.ensembl.org/Tools/
VEP). The variant, rs772176328: C>T, associated with a
splice acceptor site, but not directly affecting a canonical
base, was predicted to have a low impact on DNMT1 func-
tion. Amino acids Arg69 and Ile327 are not conserved in
mouse, dog and some primates, and variants affecting these
amino acid positions occur in control populations at fre-
quencies of greater than 1 in 112 and 1 in 10, respectively,
hence ruling them out as being significant in BWS. In con-
trast, Arg136 is conserved in all species expect dog, His1118
is conserved in all species except lamprey and Arg1223 is
conserved in all species except mouse where it is leucine.
Rare variants of DNMT1 have reduced methyltransferase
activity
To directly examine the functional impact of the three
rare DNMT1 missense variants, GFP-tagged DNMT1
recombinant proteins were generated and purified from
Hela cells (Fig. 3 a, b).
Single nucleotide substitutions within DNMT1 were
inserted using site-directed mutagenesis (Additional file 2:
Fig. 2 Structure of DNMT1 compiled from information in NCBI for NP_001124295.1 [45]. Replication fork targeting sequence (RFTS), nuclear localization
signal (NLS), bromo-adjacent homology (BAH) domain, site-specific DNA cytosine methylase activity (SSMT), zinc finger domain (CXXC). The “*” symbol
represents the translation start of the shorter DNMT1o form at amino acid 119. Conserved domains are DMAP1, RFTS, CXXC, BAH, KG linker sequence and
SSMT. Numbers represent amino acid numbering
Table 3 Missense DNMT1 variants identified in BWS cases with LOM at KCNQ1OT1 TSS-DMR
SNV ID Base change
NM_001130823.1
AA change
NP_001124295
Location
NM_001130823.1
Ch37/Hg19
location
BWS
VAF
dbSNP147
VAF
VEP
Rs
61750053
c.206G>A p.Arg69His Exon 3/41 Chr19:10291473 0.009 0.0089 Moderate
Rs 2228612 c.979A>G p.Ile327Val Exon 13/41 Chr19:10273372 0.11 0.135 Moderate
Rs
138841970
c.406C>T p.Arg136Cys Exon 4/41 Chr19:10291065 0.009 0.00028 Moderate
Rs
150331990
c.3353A>G p.His1118Arg Exon 31/41 Chr19:10251822 0.009 0.00001 Moderate
Rs
757460628
c.3668G>A p.Arg1223His Exon 33/41 Chr19:10250860 0.009 0.00002 Moderate
Variant allele frequencies were derived from dbSNP147. The variant effect predictor (VEP) tool was used to ascertain effects on protein function.
VAF variant allele frequency
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Figure S2). Wild-type and DNMT1 mutant fusion pro-
teins were expressed exclusively in the nucleus of Hela
cells (Additional file 2: Figure S3). The functional impact
of the rare missense variants on DNMT1 enzymatic ac-
tivity was examined in a trapping assay previously de-
scribed by Frauer and Leonhardt (2009) in which
substrate is irreversibly covalently bound to DNMT1.
The degree of binding is a surrogate for DNMT1 en-
zymatic activity as it measures the irreversible covalent
enzyme-DNA complex formation as the first step of the
DNA methylation reaction. Trapping activity measured
relative to that of the wild-type DNMT1 protein is
shown in Fig. 4.
The data in Fig. 4 shows that each missense variant
exhibited reduced substrate trapping activity when
compared with wild-type DNMT1 suggesting that
these variants are less efficient at maintaining DNA
methylation. Interestingly, each BWS case with these
variants exhibited a complete LOM at KCNQ1OT1
TSS-DMR as opposed to partial or mosaic LOM the
latter being a common finding in the majority of
cases. The variants are predicted to affect the func-
tion of the N terminally truncated DNMT1 form,
DNMT1o, in addition to DNMT1, although functional
effects on DNMT1o were not examined directly. In-
formation on these DNMT1 missense variants has
been submitted to Clinvar and assigned accession
numbers 3026604, 3027874 and 3028253.
It is interesting to note that DNMT1 NM_001130823.1:
c.406C>T, NP_001124295p.Arg136Cys, is located in the
N-terminal domain and shows the least reduction in
trapping activity whereas DNMT1 NM_001130823.1:
c.3668G>A, NP_001124295 p.Arg1223His, is located in
the C-terminal catalytic domain very close to the catalytic
site at p.Cys1242 and shows the maximum reduction in
trapping activity compared to wild-type DNMT1 protein.
The variant, DNMT1 NM_001130823.1: c.3353 A>G,
NP_001124295 p.His1118Arg, is located adjacent to the
glycine-lysine repeat region linking the BAH2 domain to
the C-terminal catalytic domain and has trapping ability
of approximately 50% compared to the wild-type protein.
Patient characteristics associated with variant DNMT1
Clinical features of patients with functionally impaired
DNMT1 variants of very low population frequency are
shown in Table 4. BWS has a broad clinical presentation,
and no particular feature could be ascribed to this sub-
group. All cases had methylation values at KCNQ1OT1
TSS-DMR of 0.00 indicative of a complete loss of methy-
lation in the blood. This is consistent with a defect affect-
ing methylation establishment or maintenance very early
in development either in the maternal germ cells or
pre-implantation embryo. Only one of the three cases had
loss of methylation at other imprinted loci consistent with
MLID. Patient B96 had complete LOM at the MEST locus
on chromosome 7q32.2 but maintained a normal methyla-
tion at PLAGL1 (6q24), GRB10 (7p12.1) NESPAS (20q13))
and PEG3 (19q13). Interestingly, B96 had a brother who
was stillborn, with an exomphalos and suspected BWS;
however, this baby was born prior to the availability of
molecular testing for BWS. Hence, for B96, there is a
strong likelihood of an inherited predisposition. The
mother of B97 was found to carry the R136C variant;
however, she did not have features of BWS. Parental speci-
mens from B96 and B66 were not available for testing.
These patients also had less common variants in other fol-
ate pathway genes in varying combinations. All cases had
at least two variant alleles corresponding to deleterious
folate pathway polymorphisms in association with low-
activity variants of DNMT1. These variants have been
Fig. 3 CyDye fluorescent Western blots. a HeLa cell protein lysates present in unpurified and unbound lysate fractions probed with primary antibodies
anti-GFP and anti-GAPDH and with secondary antibodies goat-anti-rabbit IgG Cy5 and goat-anti-mouse IgG Cy3. b Purified GFP-tagged DNMT1 protein
(DNMT1 225 kDa) and GFP (27 KDa) and DNMT1 variants generated by site-directed mutagenesis. The GFP bands in the fusion protein lanes in (b) likely
represent cleavage products of the purified fusion protein
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previously been shown to be associated with hypomethy-
lation either dependent or independent of folate
deficiency.
Discussion
In this paper, we have made observations that have not
been previously reported. Firstly, patients with BWS and
KCNQ1OT1 TSS-DMR LOM are more likely to have
the low-activity MTHFR variant commonly known as c.
677C>T (rs1801133: C>T) although when applying a
stringent statistical test for multiple testing, this associ-
ation was not found to be statistically significant. BWS is
a comparatively rare disorder, and examination of this
relationship in larger cohorts will be required to consoli-
date it definitively. Secondly, we identified three rare
missense variants of DNMT1 and DNMT1o and charac-
terised their capacity for maintaining DNA methylation
in vitro. All variants had impaired enzymatic activity
compared to wild-type DNMT1.
A large body of evidence has previously implicated
MTHFR rs1801133: C>T in hyper-homocysteinaemia
and DNA hypomethylation, that is potentiated by low
dietary folate and homozygosity for the T allele [17–20,
22, 34–37]. MTHFR rs1801133: C>T causes an amino
acid substitution of highly conserved alanine to valine at
position 222 (p.Ala222Val) resulting in reduced enzyme
activity due to increased thermolability [16]. Further-
more, BWS has been reported previously in association
with homocysteinuria occurring with CBS enzyme defi-
ciency [38]. Although we identified an association be-
tween the MTHFR rs1801133 T allele prevalence and
BWS that was not statistically significant by a stringent
statistical test, it remains to be determined whether a
combination of low dietary folate and vitamin B6 and
B12 deficiency, and this genotype may have a stronger
association with BWS incidence. Future studies, includ-
ing the prospective collection of dietary intake informa-
tion, will require global collaborative efforts to examine
these associations in large cohorts.
Our observations suggest that the identified low-activ-
ity DNMT1 variants may contribute to a subgroup of
BWS cases with imprinting defects through the effects
Table 4 Clinical features of BWS KCNQ1OT1 TSS-DMR LOM
cases with rare DNMT1 missense variants.
Clinical feature B66
(p.Arg1223His)
B96
(p.His1118Arg)
B97
(p.Arg136Cys)
Birth weight (kg) 3.1 4.54 3.43
Neonatal
hypoglycaemia
Y N N
Exomphalos/umbilical
hernia
Y Y N
Macroglossia Y Y Y
Macrosomia N Y Y
Ear creases Y N Y
Malignancy N N N
Facial naevus flammeus N N N
Body asymmetry N N N
Genitourinary
abnormality
N N
Hepatomegaly Y N N
Nephromegaly N N N
ART Y N N
Family history N Y (sibling
affected)
N
Sex F F M
Fig. 4 DNMT1 methyltransferase trapping activity. The relative trapping ability of each DNMT1 variant is shown as a percentage relative to wild
type DNMT1. Proteins from pEGFP-C1 transfected HeLa cells and non-transfected HeLa cells acted as controls. Technical replicates were performed in
each assay. Four biological replicate experiments were performed for each sample and controls, except for DNMT1-R136C variant for which only three
biological replicate experiments were performed. Error bars: mean ± SE
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on the maintenance methylation of hemimethylated
DNA during DNA replication prior to implantation.
Given the observation of complete loss of methylation in
all three cases with variant DNMT1, we further propose
that methylation maintenance failure at KCNQ1OT1
TSS-DMR occurs at a very early stage of embryogenesis
in the cleavage embryo. Evidence from mouse models
suggests a maternal effect on the maintenance of DNA
methylation in the pre-implantation embryo. High levels
of oocyte-derived maternal Dnmt1o are present in the
cleavage embryo and protect imprinted loci from methy-
lation loss at imprinted sites as well as in the intergenic
regions. Mothers lacking Dnmt1o have abnormal im-
printing in their offspring at the pre-implantation stage,
including abnormal X-inactivation, in addition to placen-
tal hypomethylation [39]. Human DNMT1o is similarly
expressed in mature oocytes and in early-stage embry-
onic development [32].
A direct role for DNMT1 in imprinting disorders as a
result of maternal effect mutation is also suggested by the
associations between the Uhrf1 protein and Dnmt1.
Dnmt1 is recruited by Uhrf1 to replicating DNA [40], and
intriguingly, a potentially deleterious UHRF mutation has
been recently described as having a maternal effect in
twins affected by MLID with loss of methylation [9]. Fur-
thermore, another maternal effect protein, NLRP2, impli-
cated in MLID and BWS, causes re-localization of Dnmt1
in oocytes and pre-implantation embryos [41]. Hence,
there is accumulating evidence for the potential involve-
ment of DNMT1 as a maternal effect protein associated
with loss of methylation at imprinted loci.
Of the three cases with rare missense DNMT1 alleles,
maternal inheritance of DNMT1 NM_001130823.1:
c.406C>T, NP_001124295 p.Arg136Cys, could be demon-
strated. Modes of inheritance could not be examined in
the remaining two cases due to the lack of availability of
parental DNA; however, case B96 had a sibling who was
stillborn with exomphalos who was not tested for BWS,
and the possibility of an inherited predisposition in this in-
dividual cannot be discounted. Case B66 with the variant
DNMT1 NM_001130823.1: c.3668G>A, NP_001124295
p.Arg1223His, was a female conceived by intracytoplasmic
sperm injection, and she also had a greater number of the
clinical features of BWS when compared with the other
two cases (five versus three in the other DNMT1 variant
cases). It is not known whether she had inherited the
DNMT1 variant from either of her parents; however,
maternal inheritance would be consistent with recent
observations in the mouse showing that oocytes deficient
in Dnmt1o are more susceptible to imprinting defects
following ART [42].
There was no reported indication of parental or famil-
ial BWS in any case. However, this might not be unex-
pected in a scenario where a DNMT1 mutation has a
maternal effect in the pre-implantation embryo. Mothers
may be mutation carriers themselves but unaffected if
they had inherited a deleterious DNMT1 SNV from their
fathers or had acquired one de novo. In such circum-
stances, only offspring arising from an oocyte expressing
abnormal DNMT1 protein would be affected.
Previous studies on mouse Dnmt1s have identified
regions required for maintenance of imprinting that
are localised to the region spanning amino acids
191-394; however, none of the variants in this study
are located within this domain [27]. The variant
DNMT1 NM_001130823.1: c.406C>T, NP_001124295
p.Arg136Cys, lies within an interaction site with
DNMT3A suggesting the possibility of an effect on
imprint establishment, given the evidence for coordin-
ation between DNMT1, DNMT3a and DNMT3b in
both establishing and maintaining methylation [43,
44]. Recent studies have revealed insight into the
structure of human DNMT1 protein, and conserved
domains are described for DNMT1 NP_001124295.1
in the Conserved Domain Database hosted by NCBI
[45–47]. None of the identified variants was located
directly within the enzymatic active site at Cysteine
1242 in Ref Seq NP_001124295. Variant DNMT1:
NP_001124295 p.His1118Arg is immediately adjacent to
the second bromo-adjacent homology (BAH2) domain,
and variant DNMT1: NP_001124295 p.Arg1223His lies
within the catalytic domain. Histidine at 1118 is distant (>
45 Å away) from the DNA binding, SAM binding and
catalytic cysteine within the catalytic domain. In the
DNMT1 structures, this residue is in a short helix where
it is solvent exposed and has few intra-molecular interac-
tions (structure 3PTA in [47] and structure 4WXX in
[46]). Residue Arg1223 is in the catalytic domain and dis-
tant from the DNA, SAM and Cys1242 sites (21 Å, <
15 Å, < 28 Å, respectively). This residue is leucine in
mouse Dnmt1 (structure PDB ID 4DA4 [48], and both
residues occupy similar structural space at the apex of a
loop. In the human DNMT1 structures (PDB IDS 4WXX,
3PTA), the arginine adopts two radically side chain con-
formations. In both configurations, the arginine side chain
does not engage in intra-molecular polar contacts and the
residue is solvent exposed. The loop in which the
DNMT1: NP_001124295 p.Arg1223His variant is found is
added during the evolution of cytosine C5 methyltransfer-
ases. The loop is absent in the methyltransferase from
Haemophilus parahaemolyticus (HhaI) [49] that has high
structural similarity to the mouse and human DNMT1
catalytic domain, suggesting it is an acquired adaptation
and not evolutionarily required for activity. Previous work
found that DNMT1 mutations that cause hereditary sen-
sory neuropathy were due to protein misfolding [50]. One
residue was in a hydrophobic core region while the other
was in a linker region between secondary structural
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elements. Both mutations were found to affect the folding
and stability of DNMT1 protein. In contrast, the variants
reported here are in surface-exposed regions and are
unlikely to be involved in the intra-molecular interac-
tions. Therefore, they are not proposed to affect fold-
ing or stability. However, despite sharing 80%
sequence identity, recent subtle differences in func-
tion between the mouse and human structures of
DNMT1 protein have been recently recognised [46].
Therefore, any definitive structural effects of the iden-
tified variants are currently unclear. It may be possible
that mutations exert their effects by altering conformational
flexibility that is not apparent in the crystal structure. It is
interesting to note however that the effect of the DNMT1:
NP_001124295 p.Arg1223His variant on the activity was
the strongest in the trapping assay and comparable to the
effects described for DNMT1 variants reported in the previ-
ous study examining hereditary neuropathies [50].
In a setting of maternal dietary folate deficiency or
impaired embryonic folate metabolism, the observed
decrease in DNMT1 enzymatic activity could be fur-
ther exaggerated by reduced availability of the sub-
strate S-adenosyl methionine (SAM) or increases in
inhibitory S-adenosylhomocyteine (SAH). Interestingly,
all cases with variant DNMT1 had at least two variants
predicted to adversely affect folate metabolism via the
effects directly on MTHFR and methylation of tetrahydro-
folate or via the effects on the conversion of homocysteine
to methionine via methionine synthase reductase
(MTRR) and 5-methyltetrahydrofolate-homocysteine
S-methyltransferase (MTR) using vitamin B12 as a
cofactor.
Due to their rarity in the general population, presence
in a subgroup of BWS and MLID cases, and functional
characterization supporting reduced methyltransferase
activity, these DNMT1 variants are worthy of reporting.
Ultimately, mouse models examining the effect of vari-
ant DNMT1 in the context of imprinting disruption at
specific loci including KCNQ1OT1 TSS-DMR will be
required for proof of association; however, larger cohort
studies on families with imprinting disorders are also
likely to be fruitful.
Conclusions
In conclusion, the observations from this study sug-
gest that novel genetic factors affecting DNA methy-
lation may cause imprinting disruption in a subgroup
of BWS cases. This study paves the way for larger
prospective studies in BWS and other human imprint-
ing disorders to examine the relationship between ge-
notypes linked to DNA methylation in concert with
environmental factors, to fully elucidate the causes of
abnormal genomic imprinting.
Methods
Participant recruitment
The laboratory in which this work was conducted is the
primary referral laboratory for the diagnosis of BWS in
Australasia. After diagnostic testing for BWS using
methylation-sensitive MLPA (MS-MLPA) to interrogate
imprinting defects in 11p15.5, patients with evidence of
sporadic loss of methylation at KCNQ1OT1 TSS-DMR
were invited to participate in this research project. Parents
were asked to complete a clinical questionnaire from
which data on clinical features and fertility history were
collected. The project and consent forms were approved
by the Human Research Ethics Committee of the Royal
Children’s Hospital in Melbourne (HREC 21121M), where
the work was conducted. The participant recruitment ex-
tended over a period of 5 years.
Cord blood samples used as controls were obtained from
the BMDI Cord Blood Bank at the Royal Children’s Hos-
pital, Melbourne, Australia. These samples were deemed
unsuitable for transplantation and approved for use in this
project by the local institutional ethics committee.
Molecular diagnosis of Beckwith-Wiedemann syndrome
Patients referred to the laboratory were assessed as having
BWS with isolated loss of methylation at 11p15.5
KCNQ1OT1 TSS-DMR using the Salsa ME030-B1 BWS/
RSS MS MLPA kit (MRC Holland). Patients with either
partial or complete loss of methylation at KCNQ1OT1
TSS-DMR were included in the study. H19 methylation
abnormalities and patUPD11p15 were not present in any
cases included. DNA was extracted from EDTA blood
using the Puregene kit (Qiagen Hilden Germany) and
stored at − 20 °C prior to use.
PCR and high-resolution melting
PCR was performed in a 20-μl total volume on all sam-
ples using HotStar Taq DNA Polymerase (Qiagen). Typ-
ical cycling conditions were 95 °C for 15 min followed
by 40 cycles of 95 °C for 30 s, annealing temperature for
30s, extension at 72 °C for 45 s followed by a final exten-
sion at 72 °C for 5 min. HRM reactions were performed
in a total volume of 20 μL and comprised 2× HRM Sen-
simix (Bioline) (10 μL), 0.50 μL of forward and reverse
primers at 20 μM, 1.0 μL of DNA at 10 ng/μL. Amplifi-
cation reactions were 95 °C for 10 min, followed by
40 cycles of 95 °C for 15 s, annealing temperature for
10 s, 72 °C for 10 s followed by 72 °C for 5 min. Primers
used in PCR, HRM and sequencing are described in the
Additional file 1: Tables S2a–e, S3a–e and S4a–c.
Sanger sequencing
PCR products were treated with ExoSAP-IT (USB, Affy-
metrix) and sequenced with Big Dye Terminator v3.1
(BDT) mix (Applied Biosystems) according to the
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manufacturer’s instructions. Sequences were analysed
with Mutation Surveyor v 4.0 (SoftGenetics, USA).
Variant classification
Variants were examined using Polyphen (genetics.bwh.-
harvard.edu/pph2/), SIFT (sift.bii.a-star.edu.sg) Variant Ef-
fect Prediction tool (https://www.ensembl.org/vep) [51],
Mutation Taster (www.mutationtaster.org/) and the Uni-
versity of Maryland Genetic Variant Interpretation tool.
SNVs are reported relative to their cDNA reference se-
quences where the nucleotide numbering uses + 1 as the
A of the ATG translation initiation codon. Reference se-
quences used are as follows: MTHFR NM_005957.4,
MTRR NM_002454.2, MAT1A NM_00429.2, MTR
NM_000254.2, CBS NM_001178009.1 and DNMT1
NM_001130823.1. The DNMT1 genomic reference se-
quence used for intronic variants was NC_000019.10.
Analysis of methylation at other centres of genomic
imprinting
The PLAGL (6q24), GRB10 (7p12.1), NESPAS (20q13)
and PEG3 (19q13) loci were evaluated for methylation
by pyrosequencing. Methylation at the MEST locus was
evaluated by MS-MLPA.
Genomic DNA samples from 55 BWS cases with
KCNQ1OT1 TSS-DMR LOM and from 13 controls
were bisulphite modified using the MethylEasy DNA
bisulphite modification kit (Cat No: ME-001, Human
Genetic Signatures). Pyrosequencing PCR and sequen-
cing primers were based on those described in Mackay
et al. [52]. Primers for PCR are listed in Additional file 1:
Table S5a, and primers used for sequencing are listed in
Additional file 1: Table S5b. PCR was performed in a
40-μL total volume of 1× HotStar Master mix with
0.2 μL HotStar Taq DNA Polymerase (Cat. No: 203203,
Qiagen), 0.2 μL of 20 μM forward and reverse primers,
5× Q solution (Qiagen) and 0.2 mM dNTPs. PCR cyc-
ling was at 95 °C for 15 min, followed by 45 cycles at
95 °C for 30 s, annealing temperature for 30 s and exten-
sion for 45 s at 72 °C. Pyrosequencing was performed on
a PyroMark Q24 (Cat. #9001514, Qiagen) using Pyro-
Mark Q24 Gold (Cat. #970802, Qiagen) according to the
manufacturer’s protocol. The results were analysed using
PyroMark Q24 software to determine the methylation
status. Thirteen control samples were used to establish
the mean methylation values across the CpG sites exam-
ined. A normal range was considered to be the mean
value ± two standard deviations from the mean. Patients
were scored as abnormal if methylation was outside the
established normal range. The MEST locus at 7q32.1
was examined using the SALSA MLPA kit ME032-A1
UPD7/UPD14 (MRC Holland) according to the manu-
facturer’s instructions. Two specimens previously re-
ported with genome-wide mosaic uniparental isodisomy
[53] were used as positive controls for loss of methyla-
tion. Loss of methylation at MEST was scored as positive
when methylation was < 0.35.
Generation of DNMT1 plasmids
The mammalian expression vector containing the long
isoform of wild-type human DNMT1 with N-terminal
GFP tag in pEGFP-C1 plasmid (Clontech) was obtained
from Prof. Heinrich Leonhardt (Ludwig-Maximilians-U-
niversity Biocentre, Munich). The pEGFP-C1-DNMT1
construct was transfected into competent DH5-alpha
cells, and construct fidelity was assessed by sequencing
plasmid DNA using primers designed to DNMT1 exons
as described in the supplementary information
(cDNMT1 sequencing primers).
Bacterial cultures containing pEGFP-C1-DNMT1 were
grown in 2YT and kanamycin and plasmid DNA ex-
tracted with either QIAprep Spin MiniPrep kit (Cat. #
27104, Qiagen) or Plasmid Maxi kit (Cat. #12162, Qia-
gen) appropriate to the scale of the culture and accord-
ing to the manufacturer’s instructions.
Site-directed mutagenesis
DNMT1 coding variations were inserted into the wild-
type DNMT1 sequence in pEGFP-C1. Mutagenesis was
performed with QuikChange II Site-Directed Mutagen-
esis kit (Cat. #200523, Agilent Technologies) according
to the manufacturer’s instructions. Mutagenic primer
pairs were designed for each identified DNMT1 se-
quence variant using a web-based primer design tool
(www.agilent.com/genomics/qcpd) provided by Agilent
Technologies. The primers are listed following. Mu-
tated sites are underlined:
DNMT1406C>T, F: CCAAACCCCTTTCCAAACC
TTGCACGCCCAGG, R: CCTGGGCGTGCAAGGT
TTGGAAAGGGGTTTGG; DNMT1 3353A>G, F:
GATCCTCCCAACCGTGCCCGTA GCCCT, R: AGGG
CTACGGGCACGGTTGGGAGGATC; and DNMT1
3668G>A F: CACCA ACTCCCACGGCCAGCGGC, R:
GCCGCTGGCCGTGGGAGTTGGTG.
Following selection in kanamycin (50 μg/mL), white
colonies derived from pEGFP-C1-DNMT1 mutants were
selected and sequenced to confirm the presence of the
mutation. Sequence traces from mutants are shown in
Additional file 2: Figure S2.
Transfection of DNMT1 into Hela cells
Wild-type DNMT1 and DNMT1 mutant plasmids were
transfected into HeLa cells using FugeneHD (Promega)
at a volumetric ratio of 3:1. Transfection efficiency was
analysed by flow cytometry (BD LSR II, BD Biosciences)
after 48 h. HeLa cells were transfected at a density of
1 × 105 cells per well in a 12-well plate in 1 ml of
DMEM containing 10% FCS (SAFC BioSciences) and
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incubated at 37 °C in 5% CO2. Nuclear GFP expression
was visualised by confocal microscopy on a Leica TCS
SP2. Transfection efficiencies of 60–70% were achieved.
Purification of GFP-tagged DNMT1 proteins
The GFP-Trap_A kit (Chromotek) was used to purify
GFP-tagged DNMT1 proteins from HeLa cells according
to the manufacturer’s instructions.
Protein analysis and Western blotting
Total protein estimation using the bichoninic acid (BCA)
assay (Sigma-Aldrich) was performed on 20 μL cell lysate
according to the manufacturer’s instructions. Western blot-
ting with fluorescence visualization was performed as de-
scribed in [54].
Purified GFP-tagged DNMT1 protein bound to beads
was quantified using a DNMT1 ELISA kit (Epigentek
Cat #P-3011). Standards were prepared from 7.5, 10,
12.5 and 15 ng of purified DNMT1 (supplied in the kit),
and absorbance was read at 450 and 620 nm on a Mul-
tiskan EX microplate reader (Thermo Electron).
Measurement of DNA methyltransferase activity
The DNA methyltransferase activity of the generated
wild-type and mutant DNMT1 proteins was measured
by an irreversible covalent interaction with a hemi-
methylated trapping substrate containing 5-aza-
2′-deoxycytidine (5-azadC) as described in [55] and
outlined below and in Additional file 2: Figure S4.
This reaction is designed to irreversibly “trap” active
DNMT1 in an inactive conformation by binding to
the mechanism-based inhibitor 5-azadC. Capture and
detection of this reaction intermediate serve as a
measure of DNMT1 enzyme activity. Oligonucleotides
used for the preparation of the DNA trapping sub-
strate were synthesised by Integrated DNA Technolo-
gies. The forward oligo, MG-Upper contains a
methylated cytosine (M) and the reverse 3′ end-
paired Fill-in-oligo is labelled with a MAX-NHS ester
fluorescent dye at its 5′ end. The Fill-in-oligo is comple-
mentary to the 3′ end of the MG-Upper oligonucleo-
tide. Oligo sequences were as follows: MGUpper 5′
CTCAACAACTAACTACCATCMGGACCAGAA
GAGTCATCATGG 3′ and Fill-in 5′MAXN-CCAT
GATGACTCTTCTGGTC 3′.
Double-stranded DNA generated by oligo extension was
prepared by denaturing 1 μL of each oligo at 100 μM in
NEB2 buffer at 95 °C for 2 min followed by a slow cooling
to 37 °C in a total final reaction volume of 15.2 μL. Hemi-
methylated DNA substrate was synthesised by extension
of the fill-in-oligo with the addition of 1 μL DNA Poly-
merase I (Large Klenow) fragment (Cat #M2201, Pro-
mega), 1 mM each of dTTP, dATP and dGTP (Cat
#BIO-39025, Bioline) and 50 μM 5-aza-dCTP (Cat
#NU-1118S, Jena Bioscience) in acetylated BSA at 20 ng/
μL (Cat #R3961, Promega) in a final reaction volume of
20 μL. The mix was incubated at room temperature for
10 min followed by inactivation at 75 °C for 10 min. This
preparation of trapping substrate was used immediately in
the in vitro DNMT1 trapping assay described below.
Fifteen nanograms of each purified pull-down GFP-
tagged DNMT1 protein (bead-bound) derived from each
DNMT1 protein variant was resuspended in buffer
(100 mM KCl, 10 mM Tris-HCl, pH 7.6, 1 mM EDTA,
1 mM DTT) supplemented with 100 μM S-adenosyl-L--
methionine (SAM) (New England Biolabs, Cat #B9003S),
4 μL end-labelled DNA trapping substrate (prepared as
described above) and 160 ng/μL BSA in a total reaction
volume of 200 μL. For determination of DNA methyl-
transferase activity, trapping was performed at 37 °C for
90 min with constant mixing. To remove unbound sub-
strate, beads were washed twice with 1 mL of assay buf-
fer, then resuspended in 100 μL of assay buffer and
transferred to a 96-well microplate. Bound-labelled DNA
trapping substrate associated with each variant and
wild-type DNMT1 protein was measured by fluores-
cence emission on a FLUOstar Optima microplate reader
(BMG Labtech). Technical duplicates were tested in each
assay, and assays were performed in quadruplicate for
each variant (except for DNMT1 Arg136Cys for which
triplicate assays were performed) and the mean fluores-
cence for each DNMT1 variant was normalised to the
wild-type DNMT1 fluorescence value, set to 100%. A
schematic representation of the preparation of the DNA
suicide substrate and the trapping assay is shown in
Additional file 2: Figure S4.
Statistical analysis
Calculations of chi-squared and significance values were
calculated using online analysis tools including GraphPad.
Allele association was calculated using a 2 × contingency
table with one degree of freedom [56]. Probability values
of p < 0.05 were considered to be statistically significant.
Pearson values for chi-squared and probability were calcu-
lated. Bonferroni correction was also applied for the ana-
lysis of folate pathway SNVs to adjust for multiple testing.
Additional files
Additional file 1: Table S1. Methylation at non-11p15 imprinting cen-
tres in BWS cases with loss of methylation at KCNQ1OT1 TSS-DMR. Only
samples with identified methylation changes are listed. Tables S2. a–e
Primers used for HRM of MTHFR, MTR, MTRR, MAT1A, CBS. Table S3. a–e
Primers used for sequencing MTHFR, MTR, MTRR, MAT1A, CBS. Table S4.
a–d. DNMT1 primers. Table S5 Pyrosequencing primers. (DOCX 226 kb)
Additional file 2: Figure S1. DNMT1 sequence variants identified in BWS
patients. Figure S2. Sequence traces of DNMT1 variants generated
by site-directed mutagenesis. Figure S3. Expression of GFP-tagged
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DNMT1 proteins in HeLa cells. Figure S4. Schematic of the trapping
assay adapted from Frauer and Leonhardt (2009). (PPTX 1525 kb)
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